TRH
- Category
- Brain & Cognition
- Administration routes
- InjectableNasal
- Regulatory status
- Not FDA-approved
A tripeptide that triggers pituitary release of TSH and prolactin, used off-label for effects on mood, alertness, and seizure threshold. Anticonvulsant and arousal-reversing effects have modest evidence, but neuroprotection claims rest almost entirely on animal studies. The main risk is thyroid axis disruption and blood pressure shifts, worsened by a short half-life. It is not an FDA-approved drug and is sourced as unregulated research-grade material.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Thyrotropin-Releasing Hormone (TRH) is a tripeptide (pyroGlu-His-Pro-NH2) originally discovered as the hypothalamic neurohormone responsible for stimulating thyroid-stimulating hormone (TSH) release from the anterior pituitary. Its discovery by Andrew Schally and Roger Guillemin earned them the 1977 Nobel Prize in Physiology or Medicine. However, research has revealed that TRH has remarkable neuromodulatory and neuroprotective properties that are entirely independent of its thyroid axis effects.
Beyond its classical endocrine role, TRH is widely distributed throughout the brain and spinal cord where it functions as a neurotransmitter and neuromodulator. TRH has potent analeptic (arousal-promoting) effects, acts as an endogenous anticonvulsant, protects neurons against excitotoxic damage from glutamate, and stabilizes mood and cognition. These CNS effects are mediated by TRH receptor 1 (TRH-R1) and TRH receptor 2 (TRH-R2) and involve modulation of glutamate, GABA, acetylcholine, and monoamine neurotransmission. TRH also protects against hippocampal cell death induced by excitatory amino acids.
TRH has shown therapeutic promise in clinical settings including traumatic brain injury, spinal cord injury, epilepsy, depression, and neurodegenerative diseases. Protirelin (synthetic TRH) is approved in some countries for diagnostic use and was previously used therapeutically. TRH analogs such as taltirelin (approved in Japan for spinocerebellar degeneration) extend the half-life and neuroprotective effects of the native peptide, confirming the translational potential of targeting the TRH system.
How it works in the body
Thyrotropin-Releasing Hormone is a tripeptide (pGlu-His-Pro) that activates TRH receptors in the pituitary to release TSH and prolactin. Beyond thyroid regulation, it has independent neuromodulatory effects — it acts as an endogenous anticonvulsant, counters respiratory depression, has antidepressant properties, and provides neuroprotection against excitotoxicity.
Research overview
TRH has been studied for over five decades with a dual identity: a classical hypothalamic releasing hormone and a broadly acting neuroprotective agent. Over 12,000 PubMed publications cover TRH, though the majority focus on its endocrine functions. The neuroprotective research is substantial. TRH reduced NMDA-induced excitotoxic damage in acutely dissected rat hippocampal slices (Pizzi et al., Eur J Pharmacol 1999). In traumatic brain injury models, TRH and its analogs improve neurological outcomes, reduce edema, and enhance recovery (Faden, CNS Drug Reviews 2002). A review (Alvarez-Salas et al., Int J Mol Sci 2023) summarized renewed efforts to develop TRH as a therapeutic agent, noting its anti-inflammatory, anti-apoptotic, and neurotrophic properties. The TRH analog taltirelin protects dopaminergic neurons from MPTP and rotenone toxicity in Parkinson's disease models by reducing ROS generation, lowering phosphorylated tau and alpha-synuclein, and inhibiting MAO-B activity (Zheng et al., Front Cell Neurosci 2018). TRH has also been studied in depression (it has intrinsic antidepressant-like effects), epilepsy (it is an endogenous anticonvulsant), and amyotrophic lateral sclerosis. The major limitation of TRH is its extremely short plasma half-life (~5 minutes), which has driven development of stabilized analogs.
Who researches TRH?
Commonly researched by
People exploring tissue repair and injury recovery
Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.
People researching cognitive enhancement
Studied for neuroprotective effects, memory, or cognitive performance.
People researching respiratory health
Studied for effects on lung function, bronchial health, or respiratory tissue.
Important considerations for
Those who are pregnant or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Anyone under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Those with Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Safety & interactions
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteLimited evidence: small pediatric epilepsy studies exist; they do not establish safety or efficacy for general pediatric use.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(4)
Rated by level of concern
Transient TSH and thyroid hormone elevation
ModerateProtirelin (Thyrel TRH) product labeling; standard TRH stimulation-test pharmacology
Nausea, urge to urinate, flushing (with IV administration)
LowProtirelin labeling; PubMed review of IV protirelin adverse effects (side effects described as usually mild and transient)
Very short half-life (~5 minutes) limiting therapeutic utility
LowPMID 11814729 (Kubek & Garg, 2002); PMID 17651414 (intranasal delivery rationale); PMID 22017410 (TRH analog patent review, 2011)
Blood pressure changes
ModerateProtirelin labeling; PubMed adverse-effect literature on IV protirelin (pressor responses; case reports of loss of consciousness/cardiac events)
Interaction summary(8)
Rated by direction with this peptide
Levothyroxine / liothyronine and other thyroid hormone replacement
CautionModerateExogenous thyroid hormone suppresses the pituitary and blunts or abolishes the TSH response to TRH, invalidating diagnostic testing and masking pharmacologic effect; conversely TRH on top of replacement can push a patient toward thyrotoxicosis.
Protirelin (Thyrel TRH) product labeling; standard TRH-stimulation test methodology
Glucocorticoids (dexamethasone, prednisone, hydrocortisone)
CautionModeratePharmacologic corticosteroid doses suppress TSH secretion and markedly blunt the TRH-induced TSH rise, confounding both testing and any intended endocrine effect.
Protirelin labeling (drugs that blunt TSH response); classic TRH-test endocrinology
Dopamine agonists and levodopa (dopamine, bromocriptine, cabergoline, levodopa)
CautionModerateDopaminergic tone tonically inhibits pituitary TSH and prolactin release, so these agents blunt both TRH-stimulated TSH and prolactin responses — clinically relevant in ICU patients on dopamine infusions and in Parkinson's patients.
Protirelin labeling; pituitary dopaminergic-inhibition pharmacology
Dopamine antagonists / antipsychotics and metoclopramide
CautionModerateRemoving dopaminergic inhibition amplifies the TRH-induced prolactin surge, so co-administration can produce exaggerated hyperprolactinemia (galactorrhea, menstrual disruption) on top of drug-induced prolactin elevation.
Protirelin labeling; TRH prolactin-stimulation pharmacology
Salicylates / high-dose aspirin
CautionLowSalicylates displace thyroid hormone from binding proteins and blunt the TSH response to TRH, chiefly an interference with diagnostic interpretation rather than a safety hazard.
Protirelin (Thyrel TRH) product labeling
Barbiturates and CNS depressants (including ethanol, general anesthetics)
ProtectiveLowTRH is a classic analeptic that reverses barbiturate- and ethanol-induced narcosis and hypothermia in animals independently of the thyroid axis; the arousal effect is robust preclinically but has never been established as a clinical antidote in humans.
PMID 11814729 (Kubek & Garg review, 2002); PMID 817374 (Nemeroff, 1975)
Opioids (opioid-induced respiratory depression)
ProtectiveTheoreticalTRH and its analogs counter opioid- and injury-associated respiratory depression and hypotension in animal models via non-opiate, non-naloxone-reversible mechanisms; no controlled human data support using it this way.
PMID 2830771 (Faden, TRH and opiate-antagonist review, 1988)
Antiepileptic drugs (phenobarbital and other barbiturate anticonvulsants)
SynergisticLowTRH potentiates the anticonvulsant action of phenobarbital in rodents and raises seizure threshold on its own, consistent with its role as an endogenous anticonvulsant — demonstrated preclinically and in small pediatric epilepsy series, not in controlled adult trials.
PMID 817374 (Nemeroff, 1975); PMID 11814729 (Kubek & Garg, 2002); PMID 11701274 (West/Lennox-Gastaut, 2001)
Known risks(4)
Transient TSH and thyroid hormone elevation
MildTRH stimulates TSH release, which can transiently increase thyroid hormone levels. This is clinically significant in patients with thyroid disorders. Neuroprotective effects may occur at doses that also affect the thyroid axis.
Nausea, urge to urinate, flushing (with IV administration)
Mild to ModerateCommon transient side effects when TRH is administered intravenously, as observed in diagnostic protirelin testing. Effects typically resolve within minutes.
Very short half-life (~5 minutes) limiting therapeutic utility
Pharmacokinetic LimitationNative TRH is rapidly degraded by pyroglutamyl aminopeptidase II and other enzymes. Continuous infusion or stabilized analogs are required for sustained neuroprotective effects.
Blood pressure changes
Mild to ModerateTRH can cause transient increases in blood pressure and heart rate. Patients with hypertension or cardiovascular disease should be monitored.
Drug interactions(4)
Thyroid hormones (levothyroxine, liothyronine)
TRH stimulates TSH secretion, which increases thyroid hormone production. Co-administration with exogenous thyroid hormones could produce hyperthyroid symptoms. Patients on thyroid replacement should be monitored.
Antithyroid medications (methimazole, propylthiouracil)
TRH-stimulated TSH release may partially counteract antithyroid drug effects. The interaction is generally not clinically significant at neuroprotective doses but should be considered.
Dopamine agonists (levodopa, bromocriptine, pramipexole)
Dopamine inhibits TSH release. TRH and dopamine agonists may have opposing effects on the pituitary, though neuroprotective mechanisms are distinct.
Anticonvulsant medications
TRH has intrinsic anticonvulsant activity. Additive effects with standard antiepileptic drugs are theoretically possible, potentially allowing lower doses of conventional anticonvulsants.
Research & benefits
Evidence base
- Evidence Level
- Moderate Evidence (diagnostic use approved; therapeutic analogs approved in Japan)
- Total Studies
- 12000
- Human Participants
- 2000
TRH (as protirelin) has decades of clinical use as a diagnostic agent for pituitary function testing. Its therapeutic neuroprotective potential has been demonstrated in clinical studies for TBI, depression, and spinal cord injury, but the very short half-life (~5 minutes) has limited its clinical development as a stand-alone drug. The TRH analog taltirelin (Ceredist) was approved in Japan in 2000 for spinocerebellar degeneration, validating the therapeutic concept. Several clinical trials have explored TRH in depression with positive preliminary results.
Researched for(6)
Rated by confidence in the evidence
Neuroprotection against excitotoxic cell death in hippocampal neurons
LowProtected hippocampal and cortical neurons from excitotoxic damage in animal and cell studies only.
PMID 10323261 (hippocampal slices, 1999); PMID 19666192 (cortical neurons, 2009); PMID 25446989 (hippocampal TRH from glutaminyl cyclase, 2015)
Improved neurological outcomes in traumatic brain injury models
LowImproved outcomes in animal brain-injury models. Human studies also examined prolonged disturbances of consciousness after head injury; these do not establish broad neuroprotective efficacy.
PMID 3146405 (Vink, TBI rats, 1988); PMID 8145261 (McIntosh, YM-14673, 1993); PMID 1800036 (cat head injury, 1991); PMID 2830771 (Faden review, 1988)
Protection of dopaminergic neurons in Parkinson's disease models (via taltirelin analog)
SpeculativePreliminary rodent studies suggest a TRH analog protects dopamine neurons, no human Parkinson's trials exist.
PMID 30618632 (MPTP/rotenone protection, 2018); PMID 30555300 (hemi-PD rats, 2018); PMID 39736794 (TH expression via TRHR/RARalpha, 2024)
Endogenous anticonvulsant activity — reduces seizure severity in epilepsy models
MediumReduces seizures in animal models, with supporting small open-label pediatric human studies but no modern trials.
PMID 11814729 (Kubek & Garg review, 2002); PMID 8971761 (TRH mRNA in TLE model, 1997); PMID 817374 (phenobarbital potentiation, 1975); PMID 11701274 (West/Lennox-Gastaut, 2001); PMID 17651414, 19766611 (intranasal TRH)
Analeptic/arousal-promoting effects — reverses sedation, hypothermia, hypotension
MediumReverses sedation and hypothermia in animal studies, with arousal also seen in humans given IV TRH.
PMID 11814729 (review of non-endocrine CNS actions); PMID 2830771 (Faden, CNS injury review); IV protirelin cardiovascular/arousal effects documented in human case and pharmacology literature
Antidepressant-like effects independent of thyroid axis activation
MediumHuman placebo-controlled trials from the 1970s show mixed, transient mood effects independent of thyroid changes.
PMID 810198 (IV TRH double-blind, 1975); PMID 4133645 (oral, double-blind crossover, 1974); PMID 4217458 (Benkert crossover, 1974); PMID 823828 (differential antidepressant vs endocrine effects, 1976); PMID 821075 (negative oral trial, 1976)
Benefits(6)
Neuroprotection against excitotoxic cell death in hippocampal neurons
Pizzi et al., Eur J Pharmacol 1999 (hippocampal slice model, glutamate/NMDA)
Improved neurological outcomes in traumatic brain injury models
Faden AI, CNS Drug Reviews 2002; multiple TBI studies
Protection of dopaminergic neurons in Parkinson's disease models (via taltirelin analog)
Zheng et al., Front Cell Neurosci 2018 (MPTP and rotenone models)
Endogenous anticonvulsant activity — reduces seizure severity in epilepsy models
Kubek et al., Ann Neurol 1993; Alvarez-Salas et al., Int J Mol Sci 2023 (review)
Analeptic/arousal-promoting effects — reverses sedation, hypothermia, hypotension
Multiple pharmacological studies since 1970s; reviewed in Alvarez-Salas et al., 2023
Antidepressant-like effects independent of thyroid axis activation
Prange et al., Lancet 1972; Marangell et al., Neuropsychopharmacology 1997
Key studies(3)
New Efforts to Demonstrate the Successful Use of TRH as a Therapeutic Agent (Review)
Comprehensive ReviewAlvarez-Salas E, Garcia-Luna C, de Gortari P
International Journal of Molecular Sciences
2023
Comprehensive review of TRH's neuroprotective, anti-inflammatory, and neuromodulatory effects beyond thyroid function. Summarizes evidence in TBI, depression, epilepsy, neurodegeneration, and metabolic disorders. Highlights the development of stable TRH analogs as therapeutic strategy.
Neuroprotective effect of TRH against excitatory amino acid-induced cell death in hippocampal slices
Preclinical (hippocampal slices)In vitro hippocampal preparationsAcute exposurePizzi M, Boroni F, Benarese M, et al.
European Journal of Pharmacology
1999
TRH concentration-dependently reduced NMDA-induced toxicity in acutely dissected rat hippocampal slices. Protection was sensitive to protein kinase C inhibition and was also observed when TRH was applied during NMDA exposure.
TRH Analog, Taltirelin Protects Dopaminergic Neurons From Neurotoxicity of MPTP and Rotenone
Preclinical (cell + animal model)SH-SY5Y cells + MPTP and rotenone mouse modelsIn vitro experiments; 14-day MPTP intervention and 56-day rotenone intervention in mice.Zheng C, Chen G, Tan Y, et al.
Frontiers in Cellular Neuroscience
2018
Taltirelin (TRH analog, 1 mg/kg) reduced ROS generation, rescued dopaminergic neuron viability, decreased phosphorylated tau and alpha-synuclein cleavage products, lowered MAO-B activity, and improved motor function in PD mouse models.
Regulation & availability
Why researchers look at it
TRH is far more than a thyroid trigger — it is an endogenous neuroprotective molecule with proven effects against excitotoxicity, seizures, and neurodegeneration. The approval of its analog taltirelin in Japan for cerebellar disease confirms that targeting the TRH system has real therapeutic value for brain disorders.
- FDA status
- Protirelin was previously FDA-approved as a diagnostic agent for thyroid function testing but has been discontinued in the US market. TRH is not currently FDA-approved for any therapeutic indication in the United States. Taltirelin (TRH analog) is approved in Japan but not in the US or Europe. TRH and its analogs remain under investigation for neuroprotective applications.
- WADA status
- Not listed on the 2026 WADA Prohibited List as a specific substance. However, TRH could theoretically stimulate the GH axis indirectly and its endocrine effects may draw scrutiny. Athletes should consult their anti-doping authority.
- Prescribability
- Limited — Protirelin (synthetic TRH) approved for diagnostic use in some countries; Taltirelin approved in Japan
- Availability
- Protirelin (synthetic TRH) is available as a pharmaceutical product for diagnostic use in some countries, though it has been discontinued in several markets including the US (Thypinone was withdrawn). Taltirelin (Ceredist) is approved and available in Japan for spinocerebellar degeneration. Protirelin is in FDA's 503B bulk drug substances Category 3.
International status
EU
Available for diagnostic use
US
Historically approved as protirelin for diagnostic testing; the listed US products are discontinued.
Japan
Analog taltirelin approved for spinocerebellar degeneration
Worldwide
Primarily diagnostic and experimental use
Regulatory timeline(8)
- 1969TRH structure determined independently by Schally and Guillemin
- 1977Nobel Prize in Physiology or Medicine awarded for TRH discovery
- 1976-11-05Protirelin (Thypinone; NDA 017638) approved by FDA for diagnostic testing.
- 1990sExtensive research on TRH neuroprotection in TBI, epilepsy, depression
- 2000Taltirelin (Ceredist) approved in Japan for spinocerebellar degeneration
- 2002Protirelin discontinued in the US market
- 2018Taltirelin shown to protect dopaminergic neurons in PD models
- 2023Major review renews interest in TRH as a therapeutic neuroprotective agent
Sources & FAQs
Research sources(4)
Frequently asked questions(4)
Does TRH only affect the thyroid?
No. While TRH was discovered as the trigger for TSH release, it has extensive neuromodulatory effects that are completely independent of the thyroid axis. TRH acts as a neurotransmitter throughout the brain and spinal cord, with protective effects against excitotoxicity, anti-seizure properties, arousal-promoting effects, and antidepressant activity. Many of these effects occur at doses that do not significantly alter thyroid hormone levels.
Why was the TRH analog taltirelin approved in Japan?
Taltirelin (Ceredist) was approved in Japan in 2000 for the treatment of spinocerebellar degeneration, a group of neurodegenerative diseases affecting balance and coordination. Taltirelin has a much longer half-life than native TRH and demonstrated modest but significant improvements in ataxia symptoms in clinical trials.
What is the main limitation of using TRH therapeutically?
Native TRH has an extremely short plasma half-life of approximately 5 minutes, making sustained therapeutic effects difficult to achieve. This is why research has focused on developing stabilized analogs like taltirelin, which resist enzymatic degradation and maintain activity for hours rather than minutes.
Could TRH help with traumatic brain injury?
Preclinical evidence strongly supports TRH's neuroprotective effects in TBI models, where it reduces edema, improves blood flow, and enhances neurological recovery. A small number of clinical studies have shown improvements in consciousness and outcomes in TBI patients, but large-scale trials have not been completed, partly due to TRH's short half-life.